Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00126555 · ClinicalTrials.gov registry record · Phase 2
Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00126555: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00126555 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00126555, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if giving Iressa (Gefitinib or ZD1839) with surgery and/or radiation will help to control squamous cell carcinoma of the skin. The safety of this treatment will also be studied
Interventions
- OTHER laboratory biomarker analysis
- RADIATION Radiotherapy
- DRUG Gefitinib
- PROCEDURE Conventional surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2005-03 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00126555
The ClinicalTrials.gov registry entry for NCT00126555 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00126555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00126555 about?
NCT00126555 is a clinical study titled "Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer". The goal of this clinical research study is to learn if giving Iressa (Gefitinib or ZD1839) with surgery and/or radiation will help to control squamous cell carcinoma of the skin. The safety of this treatment will also be studied
What is the current status of trial NCT00126555?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2005-03. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00126555?
The interventions under investigation include: laboratory biomarker analysis (OTHER), Radiotherapy (RADIATION), Gefitinib (DRUG), Conventional surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00126555?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.